Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor (CAR) cell therapies for light chain Amyloidosis and immune-mediated diseases. Its lead product candidate is NXC-201, which is being developed for relapsed/refractory AL Amyloidosis. The company operates in the United States and Australia, conducting clinical trials and research to advance its pipeline. Immix Biopharma aims to address unmet medical needs in these serious conditions through innovative cell therapy approaches.

Immix Biopharma, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol IMMX. The company's shares are traded in US Dollars (USD), which is the standard currency for stocks listed on US exchanges. This listing provides investors with access to the company's stock through major brokerage platforms in the United States and internationally.

Immix Biopharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing advanced therapies using biological processes, such as CAR cell therapy. The company's work in clinical-stage biopharmaceuticals places it at the intersection of drug discovery and development, targeting diseases like AL Amyloidosis and immune-mediated conditions.

Immix Biopharma is headquartered in Los Angeles, California, United States. The company was incorporated in 2012 and primarily serves the US and Australian markets. Its clinical operations and research activities are conducted in both countries, allowing it to leverage regulatory pathways and clinical trial capabilities in these regions. The company's focus on light chain Amyloidosis and immune-mediated diseases addresses patient populations in these geographies.